A
Ani Gasparyan
Researcher at Universidad Miguel Hernández de Elche
Publications - 27
Citations - 415
Ani Gasparyan is an academic researcher from Universidad Miguel Hernández de Elche. The author has contributed to research in topics: Cannabidiol & Medicine. The author has an hindex of 5, co-authored 14 publications receiving 110 citations. Previous affiliations of Ani Gasparyan include Spanish National Research Council & Carlos III Health Institute.
Papers
More filters
Journal ArticleDOI
Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders.
María Salud García-Gutiérrez,Francisco Navarrete,Francisco Navarrete,Ani Gasparyan,Ani Gasparyan,Amaya Austrich-Olivares,Francisco Sala,Jorge Manzanares,Jorge Manzanares +8 more
TL;DR: Preliminary clinical trials support the efficacy of CBD as an anxiolytic, antipsychotic, and antidepressant, and more importantly, a positive risk-benefit profile, and support the development of large-scale studies to further evaluate CBD as a potential new drug for the treatment of these psychiatric disorders.
Journal ArticleDOI
Biomarkers in Psychiatry: Concept, Definition, Types and Relevance to the Clinical Reality.
María Salud García-Gutiérrez,Francisco Navarrete,Francisco Navarrete,Francisco Sala,Ani Gasparyan,Ani Gasparyan,Amaya Austrich-Olivares,Jorge Manzanares,Jorge Manzanares +8 more
TL;DR: This review summarizes the concept and types of biomarkers including an operational definition for therapeutic development and remarking the future challenges required to reach the goal of developing valid, reliable and broadly-usable biomarkers for psychiatric disorders and their treatment.
Journal ArticleDOI
Endocannabinoid System Components as Potential Biomarkers in Psychiatry.
Francisco Navarrete,Francisco Navarrete,María Salud García-Gutiérrez,María Salud García-Gutiérrez,Rosa Jurado-Barba,Gabriel Rubio,Ani Gasparyan,Ani Gasparyan,Amaya Austrich-Olivares,Jorge Manzanares,Jorge Manzanares +10 more
TL;DR: Current evidence suggests that the components of the ECS may become promising biomarkers in psychiatry to improve, at least in part, the diagnosis and pharmacological treatment of psychiatric disorders.
Journal ArticleDOI
Role of Cannabidiol in the Therapeutic Intervention for Substance Use Disorders.
Francisco Navarrete,María Salud García-Gutiérrez,María Salud García-Gutiérrez,Ani Gasparyan,Ani Gasparyan,Amaya Austrich-Olivares,Jorge Manzanares,Jorge Manzanares +7 more
TL;DR: In this paper, the effects of CBD on the regulation of the reinforcing, motivational and withdrawal-related effects of different drugs of abuse such as alcohol, opioids (morphine, heroin), cannabinoids, nicotine, and psychostimulants (cocaine, amphetamine).
Journal ArticleDOI
Cannabis Use in Pregnant and Breastfeeding Women: Behavioral and Neurobiological Consequences
Francisco Navarrete,María Salud García-Gutiérrez,María Salud García-Gutiérrez,Ani Gasparyan,Ani Gasparyan,Amaya Austrich-Olivares,Teresa Femenía,Teresa Femenía,Jorge Manzanares,Jorge Manzanares +9 more
TL;DR: The purpose of this study was to review cannabis use during pregnancy and breastfeeding including epidemiological aspects, therapeutic or preventive strategies, and experimental considerations and results from animal models of perinatal cannabis exposure to analyze the underlying neurobiological mechanisms and to identify new therapeutic approaches.